Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: Don Hurst who wrote (2993)	4/7/2000 6:35:00 PM
From: Marty R	Read Replies (1) \| Respond to of 5665

I found this on Raging Bull. It's an excerpt from the SACI site. Does anyone track that site closely enough to know if this is a recent entry/update? The word CURE sure looks nice in there. SACI SITE INFO SB408075 Humanized monoclonal antibody to the antigen C242 (found on more than 90% of colorectal and pancreatic cancers, as well as other carcinomas). It is attached to the chemotherapeutic agent maytansine. This conjugate has induced prominent activity, including cures, in well-established tumors in preclinical studies. Given once every 3 weeks. (Approved at BAMC.) Consider for all solid tumors, but particularly for colon, pancreas, lung, breast, prostate, bladder, and other carcinomas.)

To: Don Hurst who wrote (2993)	4/7/2000 9:48:00 PM
From: Sea Otter	Respond to of 5665

IMGN Acquisition My thought for the week. I bet that at least one firm will soon make an acquisition pass at IMGN. Once some level of efficacy is shown, established pharmas would be crazy to not make the attempt. The only question is valuation. Of course, Sayare wouldn't want to sell. But everything has its price. If IMCL proves that mabs can get to market, and IMGN proves that their humanized mab conjugate platform has strong potential, then IMGN becomes a very lucrative target. So I wouldn't be surprised that we see some large spikes in price over the next 8 months, that have no obvious explanation. These would be driven purely by rumors of acquisition valuations - just like what happened to IMCL.